The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)

• Authors: SKŘIČKOVÁ Jana; BORTLÍČEK Zbyněk; HEJDUK Karel; PEŠEK M.; ZATLOUKAL P.; KOLEK V.; SALAJKA F.; KOUBKOVÁ L.; ČOUPKOVÁ H.; ZEMANOVÁ M.
• Year of publication: 2012
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine

Attached files

• Skrickovlung_cancer_006.pdf

• Description: This analysis, The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients, presented examines data obtained from the Czech population of NSCLC pts who received erlotinib.